Posted by Michael Wonder on 31 May 2023
Ibrutinib and venetoclax for untreated chronic lymphocytic leukaemia
31 May 2023 - NICE has published evidence-based recommendations on the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclyxto) for adults with untreated chronic lymphocytic leukaemia.
Ibrutinib, when used in combination with venetoclax is recommended as an option for adults with untreated chronic lymphocytic leukaemia. This is only if Janssen & AbbVie provide both medicines according to the commercial arrangements.
